{
    "info": {
        "nct_id": "NCT03845166",
        "official_title": "A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors",
        "inclusion_criteria": "* Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent.\n* Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.\n* Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.\n* Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.\n* Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 (HER-2) and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.\n* Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.\n* Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC:\n\n  * Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab)\n  * Anti-EGFR monoclonal antibody (cetuximab or panitumumab)\n  * BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations\n* Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1.\n* Tumor tissue material:\n\n  * Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.\n* Recovery to baseline or â‰¤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Adequate organ and marrow function.\n* Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.\n* Female subjects of childbearing potential must not be pregnant at screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only).\n* Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.\n* Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n* Uncontrolled, significant intercurrent or recent illness.\n* Concomitant use of certain medications.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males and > 470 ms for females. Single ECGs are no longer permitted.\n* Pregnant or lactating females.\n* Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.\n\nAdditional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:\n\n* Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.\n* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.\n\nAdditional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:\n\n* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.\n* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.",
                "criterions": [
                    {
                        "exact_snippets": "solid tumor",
                        "criterion": "solid tumor",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unresectable or metastatic",
                        "criterion": "tumor resectability or metastatic status",
                        "requirement": {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unresectable or metastatic",
                        "criterion": "tumor resectability or metastatic status",
                        "requirement": {
                            "requirement_type": "metastatic_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                        "criterion": "availability and effectiveness of life-prolonging therapies",
                        "requirement": {
                            "requirement_type": "life-prolonging therapy existence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                        "criterion": "availability and effectiveness of life-prolonging therapies",
                        "requirement": {
                            "requirement_type": "tolerability of available therapies",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                        "criterion": "availability and effectiveness of life-prolonging therapies",
                        "requirement": {
                            "requirement_type": "effectiveness of available therapies",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "solid tumor",
                        "criterion": "solid tumor",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "unresectable or metastatic",
                                "criterion": "tumor resectability or metastatic status",
                                "requirement": {
                                    "requirement_type": "resectability",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "unresectable or metastatic",
                                "criterion": "tumor resectability or metastatic status",
                                "requirement": {
                                    "requirement_type": "metastatic_status",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                                "criterion": "availability and effectiveness of life-prolonging therapies",
                                "requirement": {
                                    "requirement_type": "life-prolonging therapy existence",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                                "criterion": "availability and effectiveness of life-prolonging therapies",
                                "requirement": {
                                    "requirement_type": "tolerability of available therapies",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective",
                                "criterion": "availability and effectiveness of life-prolonging therapies",
                                "requirement": {
                                    "requirement_type": "effectiveness of available therapies",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects with metastatic CRPC (adenocarcinoma of the prostate)",
                        "criterion": "metastatic castration-resistant prostate cancer (mCRPC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "metastatic castration-resistant prostate cancer (adenocarcinoma of the prostate)"
                        }
                    },
                    {
                        "exact_snippets": "Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology",
                        "criterion": "adenocarcinoma as primary histology",
                        "requirement": {
                            "requirement_type": "primary histology",
                            "expected_value": "adenocarcinoma"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subjects with metastatic CRPC (adenocarcinoma of the prostate)",
                        "criterion": "metastatic castration-resistant prostate cancer (mCRPC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "metastatic castration-resistant prostate cancer (adenocarcinoma of the prostate)"
                        }
                    },
                    {
                        "exact_snippets": "Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology",
                        "criterion": "adenocarcinoma as primary histology",
                        "requirement": {
                            "requirement_type": "primary histology",
                            "expected_value": "adenocarcinoma"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female subjects of childbearing potential must not be pregnant at screening.",
                "criterions": [
                    {
                        "exact_snippets": "Female subjects of childbearing potential must not be pregnant at screening.",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Female subjects of childbearing potential must not be pregnant at screening.",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Tumor tissue material:",
                "criterions": [
                    {
                        "exact_snippets": "Tumor tissue material",
                        "criterion": "tumor tissue material",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Tumor tissue material",
                        "criterion": "tumor tissue material",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1.",
                "criterions": [
                    {
                        "exact_snippets": "measurable disease per RECIST 1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "measurable disease per RECIST 1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "measurable disease per RECIST 1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "measurable disease per RECIST 1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations",
                "criterions": [
                    {
                        "exact_snippets": "BRAF V600E mutations",
                        "criterion": "BRAF V600E mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "BRAF V600E mutations",
                        "criterion": "BRAF V600E mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate organ and marrow function.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate organ and marrow function",
                        "criterion": "marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.",
                "criterions": [
                    {
                        "exact_snippets": "Sexually active fertile subjects",
                        "criterion": "fertility and sexual activity status",
                        "requirement": {
                            "requirement_type": "fertile",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sexually active fertile subjects",
                        "criterion": "fertility and sexual activity status",
                        "requirement": {
                            "requirement_type": "sexually active",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use highly effective methods of contraception",
                        "criterion": "contraception use agreement",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use highly effective methods of contraception",
                        "criterion": "contraception use agreement",
                        "requirement": {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Sexually active fertile subjects",
                                "criterion": "fertility and sexual activity status",
                                "requirement": {
                                    "requirement_type": "fertile",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Sexually active fertile subjects",
                                "criterion": "fertility and sexual activity status",
                                "requirement": {
                                    "requirement_type": "sexually active",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "must agree to use highly effective methods of contraception",
                                "criterion": "contraception use agreement",
                                "requirement": {
                                    "requirement_type": "agreement to use contraception",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "must agree to use highly effective methods of contraception",
                                "criterion": "contraception use agreement",
                                "requirement": {
                                    "requirement_type": "contraception method effectiveness",
                                    "expected_value": "highly effective"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.",
                        "criterion": "small molecule kinase inhibitor receipt",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before first dose of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.",
                        "criterion": "small molecule kinase inhibitor receipt",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before first dose of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant use of certain medications.",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of certain medications",
                        "criterion": "concomitant use of certain medications",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concomitant use of certain medications",
                        "criterion": "concomitant use of certain medications",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                        "criterion": "live, attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration before first dose of study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                        "criterion": "live, attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration before first dose of study treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.",
                "criterions": [
                    {
                        "exact_snippets": "Active autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "that might deteriorate when receiving an immunostimulatory agent",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "risk of deterioration with immunostimulatory agent",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "that might deteriorate when receiving an immunostimulatory agent",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "risk of deterioration with immunostimulatory agent",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks ... before first dose of study treatment",
                        "criterion": "radiation therapy for bone metastasis",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                        "criterion": "other radiation therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "clinically relevant ongoing complications from prior radiation therapy",
                        "criterion": "ongoing complications from prior radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks ... before first dose of study treatment",
                            "criterion": "radiation therapy for bone metastasis",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 2,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                            "criterion": "other radiation therapy",
                            "requirement": {
                                "requirement_type": "time since last treatment",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "clinically relevant ongoing complications from prior radiation therapy",
                            "criterion": "ongoing complications from prior radiation therapy",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males and > 470 ms for females. Single ECGs are no longer permitted.",
                "criterions": [
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males",
                        "criterion": "QTcF (corrected QT interval by Fridericia formula) in males",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 450,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) ... > 470 ms for females",
                        "criterion": "QTcF (corrected QT interval by Fridericia formula) in females",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Single ECGs are no longer permitted",
                        "criterion": "ECG measurement method",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "single ECGs not permitted"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males",
                                "criterion": "QTcF (corrected QT interval by Fridericia formula) in males",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 450,
                                        "unit": "ms"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) ... > 470 ms for females",
                                "criterion": "QTcF (corrected QT interval by Fridericia formula) in females",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 470,
                                        "unit": "ms"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Single ECGs are no longer permitted",
                        "criterion": "ECG measurement method",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "single ECGs not permitted"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of immunodeficiency",
                        "criterion": "immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving systemic steroid therapy ... within 2 weeks prior to first dose of study treatment",
                        "criterion": "systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving systemic steroid therapy ... within 2 weeks prior to first dose of study treatment",
                        "criterion": "systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment",
                        "criterion": "immunosuppressive therapy (other than systemic steroids)",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment",
                        "criterion": "immunosuppressive therapy (other than systemic steroids)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Diagnosis of immunodeficiency",
                        "criterion": "immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "is receiving systemic steroid therapy ... within 2 weeks prior to first dose of study treatment",
                                "criterion": "systemic steroid therapy",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "is receiving systemic steroid therapy ... within 2 weeks prior to first dose of study treatment",
                                "criterion": "systemic steroid therapy",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment",
                                "criterion": "immunosuppressive therapy (other than systemic steroids)",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment",
                                "criterion": "immunosuppressive therapy (other than systemic steroids)",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled, significant intercurrent or recent illness.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled, significant intercurrent or recent illness",
                        "criterion": "intercurrent or recent illness",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of any type of anticancer antibody ... within 4 weeks before first dose of study treatment.",
                        "criterion": "anticancer antibody therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of anticancer antibody ... within 4 weeks before first dose of study treatment.",
                        "criterion": "anticancer antibody therapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of ... systemic chemotherapy ... within 4 weeks before first dose of study treatment.",
                        "criterion": "systemic chemotherapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of ... systemic chemotherapy ... within 4 weeks before first dose of study treatment.",
                        "criterion": "systemic chemotherapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of ... hormonal anticancer therapy within 4 weeks before first dose of study treatment.",
                        "criterion": "hormonal anticancer therapy",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Receipt of any type of ... hormonal anticancer therapy within 4 weeks before first dose of study treatment.",
                        "criterion": "hormonal anticancer therapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Receipt of any type of anticancer antibody ... within 4 weeks before first dose of study treatment.",
                                "criterion": "anticancer antibody therapy",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Receipt of any type of anticancer antibody ... within 4 weeks before first dose of study treatment.",
                                "criterion": "anticancer antibody therapy",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Receipt of any type of ... systemic chemotherapy ... within 4 weeks before first dose of study treatment.",
                                "criterion": "systemic chemotherapy",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Receipt of any type of ... systemic chemotherapy ... within 4 weeks before first dose of study treatment.",
                                "criterion": "systemic chemotherapy",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Receipt of any type of ... hormonal anticancer therapy within 4 weeks before first dose of study treatment.",
                                "criterion": "hormonal anticancer therapy",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Receipt of any type of ... hormonal anticancer therapy within 4 weeks before first dose of study treatment.",
                                "criterion": "hormonal anticancer therapy",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of another malignancy within 2 years before first dose of study treatment",
                        "criterion": "diagnosis of another malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of another malignancy within 2 years before first dose of study treatment",
                        "criterion": "diagnosis of another malignancy",
                        "requirement": {
                            "requirement_type": "timing relative to study treatment",
                            "expected_value": "before first dose"
                        }
                    },
                    {
                        "exact_snippets": "except for superficial skin cancers",
                        "criterion": "superficial skin cancers",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "localized, low grade tumors deemed cured and not treated with systemic therapy",
                        "criterion": "localized, low grade tumors",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "deemed cured"
                        }
                    },
                    {
                        "exact_snippets": "localized, low grade tumors deemed cured and not treated with systemic therapy",
                        "criterion": "localized, low grade tumors",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "not treated with systemic therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Diagnosis of another malignancy within 2 years before first dose of study treatment",
                                        "criterion": "diagnosis of another malignancy",
                                        "requirement": {
                                            "requirement_type": "time since diagnosis",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 2,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Diagnosis of another malignancy within 2 years before first dose of study treatment",
                                        "criterion": "diagnosis of another malignancy",
                                        "requirement": {
                                            "requirement_type": "timing relative to study treatment",
                                            "expected_value": "before first dose"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "or_criteria": [
                                        {
                                            "exact_snippets": "except for superficial skin cancers",
                                            "criterion": "superficial skin cancers",
                                            "requirement": {
                                                "requirement_type": "exception",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "localized, low grade tumors deemed cured and not treated with systemic therapy",
                                                    "criterion": "localized, low grade tumors",
                                                    "requirement": {
                                                        "requirement_type": "status",
                                                        "expected_value": "deemed cured"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "localized, low grade tumors deemed cured and not treated with systemic therapy",
                                                    "criterion": "localized, low grade tumors",
                                                    "requirement": {
                                                        "requirement_type": "treatment",
                                                        "expected_value": "not treated with systemic therapy"
                                                    }
                                                }
                                            ]
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                        "criterion": "live, attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",
                        "criterion": "live, attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:",
                "criterions": [
                    {
                        "exact_snippets": "XL092 + Avelumab Combination Therapy Cohorts ONLY",
                        "criterion": "treatment cohort",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": "XL092 + Avelumab combination therapy cohorts only"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "XL092 + Avelumab Combination Therapy Cohorts ONLY",
                        "criterion": "treatment cohort",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": "XL092 + Avelumab combination therapy cohorts only"
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component)",
                        "criterion": "renal cell carcinoma (RCC) histology",
                        "requirement": {
                            "requirement_type": "histological subtype",
                            "expected_value": [
                                "clear cell",
                                "clear cell with sarcomatoid component"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "previously treated advanced RCC",
                        "criterion": "renal cell carcinoma (RCC) stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    },
                    {
                        "exact_snippets": "previously treated advanced RCC",
                        "criterion": "renal cell carcinoma (RCC) prior treatment",
                        "requirement": {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed following treatment",
                        "criterion": "disease progression",
                        "requirement": {
                            "requirement_type": "progression after treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "prior systemic anticancer regimens",
                        "requirement": {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "prior systemic anticancer regimens",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "inoperable locally advanced",
                                "metastatic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "Expansion Cohorts B and E (nccRCC)",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "cohort",
                            "expected_value": [
                                "Expansion Cohort B",
                                "Expansion Cohort E"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Subjects with previously treated advanced RCC",
                        "criterion": "renal cell carcinoma (RCC)",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": "advanced"
                        }
                    },
                    {
                        "exact_snippets": "Subjects with previously treated advanced RCC",
                        "criterion": "renal cell carcinoma (RCC)",
                        "requirement": {
                            "requirement_type": "treatment history",
                            "expected_value": "previously treated"
                        }
                    },
                    {
                        "exact_snippets": "non-clear cell histology",
                        "criterion": "tumor histology",
                        "requirement": {
                            "requirement_type": "histology type",
                            "expected_value": "non-clear cell"
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed following treatment",
                        "criterion": "disease progression",
                        "requirement": {
                            "requirement_type": "progression evidence",
                            "expected_value": "radiographic progression after treatment"
                        }
                    },
                    {
                        "exact_snippets": "at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "prior systemic anticancer therapy",
                        "requirement": {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "prior systemic anticancer therapy",
                        "requirement": {
                            "requirement_type": "disease extent",
                            "expected_value": [
                                "inoperable locally advanced",
                                "metastatic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab)",
                "criterions": [
                    {
                        "exact_snippets": "Fluoropyrimidine",
                        "criterion": "fluoropyrimidine",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "irinotecan",
                        "criterion": "irinotecan",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "oxaliplatin",
                        "criterion": "oxaliplatin",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "with or without an anti-VEGF monoclonal antibody (bevacizumab)",
                        "criterion": "anti-VEGF monoclonal antibody (bevacizumab)",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": "optional"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Fluoropyrimidine",
                        "criterion": "fluoropyrimidine",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "irinotecan",
                        "criterion": "irinotecan",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "oxaliplatin",
                        "criterion": "oxaliplatin",
                        "requirement": {
                            "requirement_type": "treatment exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent.",
                "criterions": [
                    {
                        "exact_snippets": "Cytologically or histologically confirmed solid tumor",
                        "criterion": "solid tumor",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "cytologically",
                                "histologically"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "inoperable locally advanced, metastatic, or recurrent",
                        "criterion": "tumor stage/status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "inoperable locally advanced",
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.",
                        "criterion": "tumor tissue sample",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "archival",
                                "fresh"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.",
                        "criterion": "tumor tissue sample",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.",
                        "criterion": "tumor tissue sample",
                        "requirement": {
                            "requirement_type": "safety of obtaining sample",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Recovery to baseline or â‰¤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Recovery to baseline or â‰¤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments",
                        "criterion": "adverse events (AEs) related to any prior treatments",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "CTCAE grade"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Recovery to baseline or â‰¤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments",
                        "criterion": "adverse events (AEs) related to any prior treatments",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": [
                                "recovered to baseline",
                                "â‰¤ Grade 1 severity"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs) related to any prior treatments",
                        "requirement": {
                            "requirement_type": "clinical_significance",
                            "expected_value": "nonsignificant"
                        }
                    },
                    {
                        "exact_snippets": "unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                        "criterion": "adverse events (AEs) related to any prior treatments",
                        "requirement": {
                            "requirement_type": "stability_on_supportive_therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC:",
                "criterions": [
                    {
                        "exact_snippets": "histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum",
                        "criterion": "adenocarcinoma of the colon or rectum",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum",
                        "criterion": "adenocarcinoma of the colon or rectum",
                        "requirement": {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum",
                        "criterion": "adenocarcinoma of the colon or rectum",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "KRAS/NRAS wild-type (confirmed via local testing report)",
                        "criterion": "KRAS/NRAS mutation status",
                        "requirement": {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    },
                    {
                        "exact_snippets": "KRAS/NRAS wild-type (confirmed via local testing report)",
                        "criterion": "KRAS/NRAS mutation status",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "local testing report"
                        }
                    },
                    {
                        "exact_snippets": "determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing",
                        "criterion": "microsatellite instability/mismatch repair status",
                        "requirement": {
                            "requirement_type": "MSI status",
                            "expected_value": "not MSI-high"
                        }
                    },
                    {
                        "exact_snippets": "determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing",
                        "criterion": "microsatellite instability/mismatch repair status",
                        "requirement": {
                            "requirement_type": "MMR status",
                            "expected_value": "not dMMR"
                        }
                    },
                    {
                        "exact_snippets": "determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing",
                        "criterion": "microsatellite instability/mismatch repair status",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "local testing"
                        }
                    },
                    {
                        "exact_snippets": "received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC",
                        "criterion": "prior chemotherapy for metastatic CRC",
                        "requirement": {
                            "requirement_type": "prior therapy",
                            "expected_value": "standard of care chemotherapy regimens"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Anti-EGFR monoclonal antibody (cetuximab or panitumumab)",
                "criterions": [
                    {
                        "exact_snippets": "Anti-EGFR monoclonal antibody (cetuximab or panitumumab)",
                        "criterion": "anti-EGFR monoclonal antibody treatment",
                        "requirement": {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "cetuximab",
                                "panitumumab"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 (HER-2) and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "breast cancer",
                        "criterion": "breast cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hormone receptor positive (ER+ and/or PR+)",
                        "criterion": "hormone receptor status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "hormone receptor positive (ER+ and/or PR+)",
                        "criterion": "hormone receptor status",
                        "requirement": {
                            "requirement_type": "receptor_types",
                            "expected_value": [
                                "ER",
                                "PR"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative for human epidermal growth factor receptor 2 (HER-2)",
                        "criterion": "HER-2 status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "disease progression after prior systemic anticancer regimen",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "disease progression after prior systemic anticancer regimen",
                        "requirement": {
                            "requirement_type": "method_of_progression",
                            "expected_value": "radiographically"
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "disease progression after prior systemic anticancer regimen",
                        "requirement": {
                            "requirement_type": "number_of_prior_regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    },
                    {
                        "exact_snippets": "radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease",
                        "criterion": "disease progression after prior systemic anticancer regimen",
                        "requirement": {
                            "requirement_type": "disease_stage",
                            "expected_value": [
                                "inoperable locally advanced",
                                "metastatic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:",
                "criterions": [
                    {
                        "exact_snippets": "XL092 + Atezolizumab Combination Therapy Cohorts ONLY",
                        "criterion": "treatment cohort",
                        "requirement": {
                            "requirement_type": "combination therapy",
                            "expected_value": [
                                "XL092",
                                "Atezolizumab"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "adequate treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "treatment modalities",
                            "expected_value": [
                                "radiotherapy",
                                "surgery",
                                "radiosurgery"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.",
                        "criterion": "brain metastases or cranial epidural disease",
                        "requirement": {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant or lactating females.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "lactating females",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating females",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only).",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with XL092 (all cohorts)",
                        "criterion": "prior treatment with XL092",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only)",
                        "criterion": "prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only)",
                        "criterion": "prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor",
                        "requirement": {
                            "requirement_type": "cohort restriction",
                            "expected_value": [
                                "E",
                                "F",
                                "G",
                                "H"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "prior treatment with regorafenib and/or TAS-102 (Cohort H only)",
                        "criterion": "prior treatment with regorafenib and/or TAS-102",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior treatment with regorafenib and/or TAS-102 (Cohort H only)",
                        "criterion": "prior treatment with regorafenib and/or TAS-102",
                        "requirement": {
                            "requirement_type": "cohort restriction",
                            "expected_value": [
                                "H"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}